DC FieldValueLanguage
dc.contributor.authorLazaridou, Elizabeth-
dc.contributor.authorKourlaba, Georgia-
dc.contributor.authorRavanidis, Stylianos-
dc.contributor.authorGounelas, George-
dc.contributor.authorStefanou, Garyfallia-
dc.contributor.authorTsolakidis, Anastasios-
dc.contributor.authorMathioudakis, Konstantinos-
dc.contributor.authorApalla, Zoe-
dc.date.accessioned2025-03-07T15:19:08Z-
dc.date.available2025-03-07T15:19:08Z-
dc.date.issued2024-07-06-
dc.identifierscopus-85210548946-
dc.identifier.issn1365-2230-
dc.identifier.issn0307-6938-
dc.identifier.other85210548946-
dc.identifier.urihttps://uniwacris.uniwa.gr/handle/3000/3012-
dc.description.abstractBackground. Drug persistence is a crucial aspect of treatment success in psoriasis. Objectives. To record real-world evidence concerning drug survival of biologic agents used for psoriasis treatment and to detect associated modifying factors in Greece. Methods. This was a retrospective cohort study based on data extracted from the nationwide Greek prescription system. Included patients had psoriasis, with or without concomitant psoriatic arthritis (PsA), and had initiated biologics between 1 January 2016 and 31 December 2020. Results. We included 8819 patients who received 13 359 treatment lines. Among them, 76.8% of patients were biologic naive and 16.5% were diagnosed with concomitant PsA. The overall median drug survival was 34.3 months [95% confidence interval (CI) 32.6–36.5]. Drug persistence at 12, 24, 36 and 48 months of follow-up was 71.9%, 57.7%, 49.0% and 43.7%, respectively. Patients receiving brodalumab had the highest drug survival rate in the first 2 years, while secukinumab had the highest rates beyond this period. Overall, drug survival rates were higher in the first treatment line (median 51.1 months, 95% CI 47.1 to not reached) than in the second line and onwards (median 21.7 months, 95% CI 20.0–23.5). Treatment line, PsA status, age and sex were found to significantly affect drug survival rates. Conclusions. Our findings confirm previous reports regarding the importance of efficient first-line biologics and the vulnerability of patients to coexistent PsA. The use of antibodies against interleukins confers high drug survival rates. These results will assist clinical management of patients with psoriasis in Greece.en_US
dc.language.isoenen_US
dc.relation.ispartofClinical and Experimental Dermatologyen_US
dc.titleDrug survival of biologics in patients with psoriasis: real-world evidence for Greece during the period 2016–2020en_US
dc.typeArticleen_US
dc.identifier.doi10.1093/ced/llae240en_US
dc.identifier.scopus2-s2.0-85210548946-
dcterms.accessRights0en_US
dc.relation.deptDepartment of Archival, Library and Information Studiesen_US
dc.relation.facultySchool of Administrative, Economics and Social Sciencesen_US
dc.relation.volume49en_US
dc.relation.issue12en_US
dc.identifier.spage1573en_US
dc.identifier.epage1581en_US
dc.collaborationUniversity of West Attica (UNIWA)en_US
dc.subject.fieldMedical and Health Sciencesen_US
dc.journalsSubscriptionen_US
dc.publicationPeer Revieweden_US
dc.countryGreeceen_US
local.metadatastatusverifieden_US
item.fulltextNo Fulltext-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.openairetypeArticle-
item.languageiso639-1en-
item.grantfulltextnone-
crisitem.author.deptDepartment of Archival, Library and Information Studies-
crisitem.author.facultySchool of Administrative, Economics and Social Sciences-
crisitem.author.orcid0000-0001-7364-4542-
crisitem.author.parentorgSchool of Administrative, Economics and Social Sciences-
Appears in Collections:Articles / Άρθρα
CORE Recommender
Sorry the service is unavailable at the moment. Please try again later.
Show simple item record

SCOPUSTM   
Citations

1
checked on Apr 7, 2025

Page view(s)

13
checked on Apr 8, 2025

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.